Ocean Biomedical, Inc.
Ocean Biomedical, Inc. (OCEA): 7 pipeline candidates · ~9 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
8.5 months
D/E -1.02 · 0% dilution
Lead: Approved
7 candidates
N/A
N/A
A transparent, data-derived signal for Ocean Biomedical, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$46K
Cash
$800K
Quarterly Burn
$356K
Runway
8.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| chi3l1 bsabs | Preclinical |
| chi3l1 mab | Preclinical |
| chit1 small molecule | Preclinical |
| fludeoxyglucose f18 | Approved |
| malaria vaccine candidate | Preclinical |
| pfgarp mab | Preclinical |
| pfgarp small molecule | Preclinical |
Frequently asked questions
How many drug candidates are in Ocean Biomedical, Inc.'s pipeline?
Ocean Biomedical, Inc. (OCEA) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Ocean Biomedical, Inc.'s lead drug candidate?
Ocean Biomedical, Inc.'s most advanced tracked candidate is chi3l1 bsabs (Preclinical) for Non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM).
What is Ocean Biomedical, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Ocean Biomedical, Inc. has approximately 8.5 months of cash runway.
What is Ocean Biomedical, Inc.'s market capitalization?
Ocean Biomedical, Inc.'s market capitalization is approximately $46K.
Who is the CEO of Ocean Biomedical, Inc.?
Michelle Berrey, M.D. is the chief executive officer of Ocean Biomedical, Inc. (OCEA).
Get the full picture on Ocean Biomedical, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.